# Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Source: https://onco.cc/trials/nct04422366/  
OnCo record `nct04422366` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of HPV quadrivalent vaccine in cervical cancer and vulvar cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.

## Summary

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females is a phase 3 interventional study registered as NCT04422366 by Shanghai Bovax Biotechnology Co., Ltd., with 8000 participants planned, started 2020-04-28 and due to reach its primary completion in 2027-09-15. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®. Conditions listed: Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04422366
- Phase: 3
- Setting: A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years
- Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- Enrolled: 8000

## Sources

- ClinicalTrials.gov NCT04422366: https://clinicaltrials.gov/study/NCT04422366

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Vaginal cancer](https://onco.cc/cancers/vaginal/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- drugs: [HPV quadrivalent vaccine (types 6, 11, 16 and 18)](https://onco.cc/drugs/hpv-quadrivalent-vaccine/)

---
JSON: https://onco.cc/api/v1/entities/nct04422366.json